The 2025 Best Firms to Work For: SSI Strategy

CONSULTING SERVICE LINES: Strategy, Operations Management

At SSI Strategy, our mission is to build better biotech companies by offering an alternative path to success. We understand that the traditional route of building a biotech company can be filled with challenges and delays. Our multidisciplinary team serves as a seamless, valuable and reliable partner for clients, providing biotech leaders with the right resources at their fingertips to make the most informed decisions. We offer deep expertise, strategic insight, and comprehensive services through our flexible "Build—Scale—Transition" model. Our Strategic Medical Office integrates clinical development, medical affairs, safety, and regulatory strategy to ensure patient-centric, value-focused decisions. From expert advice to the latest technology options and identifying funding opportunities, we remove obstacles in decision-making processes, saving time and money while enabling clients to bring life-saving medicines to patients without unnecessary delays. Regardless of company maturity, team size or therapeutic area, we strive to be the trusted long-term partner that biotech leaders turn to for innovative solutions and collaborative achievement of significant milestones.

CMAG: What characteristics and elements would you attribute to your firm’s inclusion as a Best Firm to Work For?

Our approach centers on providing clients with an alternative path to success through meaningful partnerships and measurable outcomes. Three core elements drive engagement: a partnership model that enables consultants to own outcomes and remove obstacles in client decision-making rather than simply augment staff, a multidisciplinary team of medical, scientific, regulatory, and business operators who serve as seamless and reliable partners, and intentional growth through mentorship, rotations and clear leadership pathways. Our Strategic Medical Office approach ensures work remains meaningful by connecting daily execution to patient impact and bringing life-saving medicines to patients without unnecessary delays. We cultivate psychological safety, constructive feedback, and flexible working arrangements that enable teams to deliver their best work. This combination of purposeful work, expert collaboration, and genuine development opportunities creates high engagement and strong retention while empowering biotech leaders to make the most informed decisions.

CMAG: Are there any specific programs or initiatives that contributed to you being included as a Best Firm?

Several key initiatives have strengthened our workplace culture this year. Our mentoring programs connect team members across experience levels and practice areas, fostering both professional development and knowledge transfer. We created service hubs and sub-hubs to let colleagues develop their specialist skills and collaborate with other experts in their area, deepening expertise while building cross-functional relationships. AI Coffee and Bot sessions provide informal training opportunities where we explore practical applications of emerging technologies and their implications for biotech development. Information sharing initiatives keep our team current on regulatory developments, industry trends, and best practices across our therapeutic focus areas. Global mentorship and cross-functional collaboration expand professional networks and build diverse skill sets. These complement our regular team meetings, company-wide communications and management support programs, creating an environment where continuous learning and meaningful professional relationships thrive.

CMAG: In describing your firm, what would you say sets it apart from other consulting firms?

We offer biotech leaders an alternative path to success through our flexible "Build—Scale—Transition" model. Our multidisciplinary team brings together seasoned medical and regulatory leaders with experienced operators and consultants, serving as seamless, valuable, and reliable partners for our clients. We partner closely with CMOs and leadership teams, providing the right resources at their fingertips and appropriately scaled capabilities at each development stage, then support clients as they internalize these functions when ready. Our Strategic Medical Office offering integrates clinical development, medical affairs, safety, and regulatory strategy to ensure decisions remain patient-centric and value-focused. We're committed to removing obstacles in the decision-making process, saving time and money while enabling clients to bring life-saving medicines to patients without unnecessary delays. This partnership approach embodies our commitment to Building Better Biotechs and creates the meaningful work environment that attracts and retains exceptional talent.

CMAG: Where your workforce is concerned, what would you say your priorities look like for the upcoming year and beyond?

We're focusing on four key areas that align with our partnership model and client needs. First, building capabilities for emerging challenges—AI literacy and compliant implementation, decentralized and hybrid trial expertise, and documentation that meets evolving FDA and EMA expectations. Second, developing leadership at every level through clear advancement pathways, mentoring programs and management enablement. Third, fostering belonging and well-being through psychological safety, flexible work arrangements and inclusive collaboration. Fourth, enhancing global teamwork through expanded cross-practice rotations that accelerate professional growth. These priorities ensure our team remains market-relevant and client-ready as regulatory guidance continues to evolve, while maintaining the culture of ownership and meaningful impact that defines our workplace.

CMAG: What opportunities do you see as the most promising?

We're seeing growing demand for AI integration in clinical development, particularly around documentation standards and regulatory compliance frameworks. The continued evolution toward decentralized and hybrid trial designs reflects sponsors' focus on more efficient patient engagement. Strong regulatory approval trends from 2024 are creating opportunities for well-prepared programs, while increased attention to quality and compliance presents openings as companies navigate evolving regulatory expectations.

CMAG: What market forces do you see as the most challenging?

Funding constraints are affecting biotech timelines, with more selective investment decisions and limited IPO activity creating execution challenges. Pricing pressures from IRA implementation are beginning to influence portfolio strategies, while regulatory uncertainty persists as AI and clinical diversity guidelines continue to develop across US and EU markets.

CMAG: What impact do you think Best Firm to Work For honors will have on your employees? The firm overall? Clients?

For our team, this recognition validates the culture we've built together—one characterized by high trust, continuous growth, and meaningful impact on bringing life-saving medicines to patients. For talent acquisition, it serves as a clear signal that helps us attract exceptional medical, scientific, regulatory, and operational professionals who share our commitment to Building Better Biotechs and providing an alternative path to success. For clients, it reinforces confidence that engaged teams deliver superior outcomes, serve as trusted long-term partners, and remain committed to collaborative achievement of significant milestones from initial design through submission and launch. This recognition strengthens our fundamental approach: strong culture drives exceptional talent, which delivers outstanding client outcomes by removing obstacles in decision-making and saving time and money, which further strengthens our culture. This virtuous cycle is exemplified in our Strategic Medical Office focus and partnership-driven model, creating lasting value for all stakeholders while revolutionizing how biotech leaders access the right resources at their fingertips.